FDA okays ResApp’s (ASX:RAP) SleepCheckRx; how are shares faring?

Be the First to Comment Read

FDA okays ResApp’s (ASX:RAP) SleepCheckRx; how are shares faring?

 FDA okays ResApp’s (ASX:RAP) SleepCheckRx; how are shares faring?
Image source: © Stockbakery | Megapixl.com

Highlights

  • ResApp Health receives the US Food and Drug Administration (FDA) clearance for its SleepCheckRx mobile application
  • SleepCheckRx is a sleep test that analyses the risk of moderate to severe obstructive sleep apnoea in adults by probing breathing and snore sounds recorded on an Apple iPhone
  • ResApp plans to seek 510(k) clearance for Android devices in the future

ResApp Health Limited (ASX: RAP), a digital health company, has received the US Food and Drug Administration (FDA) clearance for its at-home sleep test SleepCheckRx. This clearance opens a substantial market prospect for ResApp as over 20 million adults in America suffer from sleep apnoea. The company can now commercially sell the test in the United States.

SleepCheckRx is a sleep test (mobile application) that can be used at home. It analyses the risk of moderate to severe obstructive sleep apnoea in adults by probing breathing and snore sounds recorded on an Apple iPhone. It does not require any other accessories.

SleepCheckRx has got 510(k) clearance from FDA as a prescription-only software-as-a-medical device. ResApp plans to seek 510(k) clearance for Android devices in the future.

What is sleep apnoea?


Sleep apnoea is a breathing disorder
© Tommaso79 | Megapixl.com

Sleep apnoea is a very common sleep breathing disorder, and its prevalence is growing due to the increasing ageing population and increasing rates of obesity. The condition affects over three out of ten men and almost two out of ten women. Studies indicate that almost 80% of people with sleep apnoea are unaware of the condition and are untreated.

Obstructive sleep apnoea is a condition when the air stops flowing to the lungs during sleep.

Patients can avail SleepCheckRx through a prescription from their healthcare providers. A specific code will be given to them for downloading the application from mobile Appstore. Their results will be uploaded to the portal of the healthcare provider.

SleepCheckRx was assessed in 220 patients in an at-home clinical trial, compared to simultaneous polysomnography, which is a study designed to identify sleep disorders. The app’s algorithm correctly identified 89.3% of patients with moderate to severe sleep apnoea with a 77.6% specificity.

Australian and Japanese patents

Yesterday (05 July), the company bagged a patent entitled “Methods and apparatus for cough detection in background noise environments”. The patent was granted in Australia and Japan. It covers the use of machine learning audio processing techniques for detecting cough sounds in settings with considerable background noise.

Stock information

At the time of writing this article (as on WED 06 JUL at 11:51 AM AEST), shares of RAP were trading at AU$0.132.

Disclaimer

Speak your Mind

Featured Articles

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK